5 completed, 1 recruiting, 1 withdrawn. 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 4, Recruiting 1 |
Follow Nykode Therapeutics ASA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. VB10.16, Atezolizumab Injection [Tecentriq], Placebo - HPV-Related Cervical Carcinoma, HPV-Related Malignancy | Phase 2 | Withdrawn | Nykode Therapeutics ASA | 2024-04-18 | 2024-09-20 | |
| Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma VB10.16, Pembrolizumab - HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC | Phase 1 / Phase 2 | Recruiting | Nykode Therapeutics ASA | 110 | 2023-12-19 | 2026-08-26 |
| Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors VB10.NEO - Solid Tumors, Adult | Phase 1 | Completed | Nykode Therapeutics ASA | 26 | 2021-12-21 | 2024-12-03 |
| A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers VB10.2129, VB10.2210 - COVID-19, Infection Viral | Phase 1 / Phase 2 | Completed | Nykode Therapeutics ASA | 68 | 2021-11-01 | 2024-04-11 |
| Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer VB10.16, Atezolizumab - Cervical Cancer, Cervix Cancer | Phase 2 | Completed | Nykode Therapeutics ASA | 52 | 2020-07-01 | 2023-12-15 |
| A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer VB10.NEO, Bempegaldesleukin - Locally Advanced or Metastatic Solid Tumours | Phase 1 / Phase 2 | Completed | Nykode Therapeutics ASA | 41 | 2018-04-04 | 2023-04-21 |
| An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) VB10.16 Immunotherapy (DNA vaccine) - High Grade Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | Nykode Therapeutics ASA | 34 | 2015-08-01 | 2022-07-13 |
Neoplasm Metastasis (4) · Recurrence (3) · Uterine Cervical Neoplasms (2) · COVID-19 (1) · Carcinoma, Renal Cell (1) · Coronavirus Infections (1) · Infections (1) · Melanoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Virus Diseases (1)
atezolizumab (3) · Biological Products (1) · VB10.COV-2 vaccine (1) · Vaccines (1) · Vaccines, DNA (1) · bempegaldesleukin (1) · pembrolizumab (1)
Germany (5) · Norway (3) · Poland (2) · Spain (2) · Belgium (1) · Bulgaria (1) · Czechia (1) · France (1) · Hungary (1) · United Kingdom (1) · United States (1)
Siri Torhaug, MD (2) · Ritu Salani, MD MBA (1)